Adagio Medical to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceFeb 2, 2026 8:05 AM Eastern Standard Time# Adagio Medical to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceShare---LAGUNA HILLS, Calif.--([BUSINESS WIRE])--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio†or "the Company†), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today a ...

LAGUNA HILLS, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Adagio Medical Holdings, Inc. (NASDAQ: ADGM), based in Laguna Hills, CA, a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Company management will present live at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com, on February 5, 2026 DATE: February 5thTIME: 1:30 PM ET REGISTER HERE Available for 1x1 meetings: February 12 and 13. Schedule 1x1 Meeti ...

Core Insights - Adagio Medical Holdings, Inc. announced preliminary results from the FULCRUM-VT Study, demonstrating 97.4% acute clinical success in treating Sustained Monomorphic Ventricular Tachycardia (SMVT) using their proprietary Ultra-Low Temperature Cryoablation (ULTC) technology [1][2][5] Study Overview - The FULCRUM-VT Study involved 207 patients across 19 sites in the U.S. and Canada, focusing on both ischemic and non-ischemic cardiomyopathy [2][8] - The study reported a mean procedure duration of 206 minutes and a 2.5% rate of major adverse events, including four peri-procedural deaths [2][4] Efficacy and Safety Results - Acute clinical success was defined as the non-inducibility of target ventricular arrhythmias, achieved in 97.4% of cases, with 96.7% of patients having all clinically relevant ventricular tachycardias eliminated [2][4] - The safety profile of the ULTC system was deemed favorable, with a low rate of major adverse events [4][5] Future Outlook - The company plans to present six-month primary efficacy endpoint results at the Heart Rhythm 2026 conference, indicating ongoing commitment to research and development [4][5] - The FULCRUM-VT Study aims to support FDA premarket approval for the vCLAS™ Cryoablation System, potentially leading to broader indications for treating scar-mediated VT [8][9]